Chris Viehbacher, Biogen CEO (Photographer: Scott Eells/Bloomberg via Getty Images)
January 5, 2023 10:32 AM ESTUpdated 03:32 PM
People
Bioregnum
R&D

Chris Viehbach­er once again sets out to re­vamp R&D at a ma­jor bio­phar­ma. The last try led to his ouster

An out­spo­ken Chris Viehbach­er spent six years try­ing un­suc­cess­ful­ly to prod Sanofi’s multi­bil­lion-dol­lar R&D group in­to a more pro­duc­tive phase that re­lied less on part­ners …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

A service from the Financial Times